FDG PET/CT and breast cancer

By Kristin Schmiedehausen, MD

|2015-01-02

Breast cancer is the most common cause of cancer death in women.1 PET/CT using Fludeoxyglucose F18 injection (18F FDG) can impact staging and restaging of breast cancer, especially in patients with inflammatory, locally advanced and metastatic breast cancer. Download the white paper to learn about the increasing role PET/CT has in breast cancer in addition to breast cancer treatment guidelines and reimbursement options for certain countries.

1
Subscription Button Icon

Keep up to date on the latest trends in healthcare. Read about current developments, new products and upcoming events.